Cantor Fitzgerald Equities Analysts Lift Earnings Estimates for Adlai Nortye Ltd. (NASDAQ:ANL)

Adlai Nortye Ltd. (NASDAQ:ANL) – Investment analysts at Cantor Fitzgerald upped their FY2024 earnings per share estimates for shares of Adlai Nortye in a research note issued to investors on Tuesday, April 23rd. Cantor Fitzgerald analyst L. Chen now anticipates that the company will earn ($2.41) per share for the year, up from their previous estimate of ($2.50). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Adlai Nortye’s current full-year earnings is ($2.90) per share.

Adlai Nortye Trading Down 0.7 %

Shares of NASDAQ ANL opened at $13.46 on Thursday. Adlai Nortye has a 12-month low of $7.11 and a 12-month high of $19.30. The stock has a fifty day moving average price of $9.33 and a 200 day moving average price of $9.31.

Institutional Trading of Adlai Nortye

An institutional investor recently raised its position in Adlai Nortye stock. Cantor Fitzgerald L. P. grew its holdings in shares of Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 40,310 shares of the company’s stock after acquiring an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned about 0.11% of Adlai Nortye worth $362,000 as of its most recent SEC filing. Institutional investors and hedge funds own 35.21% of the company’s stock.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.